Biomarkers

Share:
ResearchersAgainstAlzheimer's would like to thank Roche Diagnostics for their support of this project.
Return to the full list of Biomarkers

Brain-derived neurotrophic factor (BDNF)

Method of Measurement (Pre-analytical Tools)
Blood/Plasma
Generic
Biomarker Measured
Genetic variation/DNA
Neuronal damage
Use
Diagnostic
Monitoring
Stage of Development
Clinical trials
Active vs Completed Trials
Completed
Aim/Results

Some studies have found decreased BDNF in platelet rich plasma of patients with Alzheimer’s disease, while others have shown a compensatory increase in BDNF levels in the plasma of people with AD. Additionaly patients with the BDNF genetic polymorphism Val66Met showed a significantly faster rate of decline on verbal and visual EM, and language.

What is Required from Patients

blood draw, mild discomfort, in clinic visits

What is Required from the Health System

phlebotomist, equipped lab (e.g., centrifuge), a way to measure the peptide (e.g., mass spectrometer, protein assay kit, ELISA, or western blot), genetic testing (e.g., qPCR)

Sponsor

Charles University in Prague and General University Hospital in Prague; Universidade Federal de Minas Gerais; Instituto Hermes Pardini; University of Melbourne; Brown University; Rhode Island Hospital; Austin Health, Heidelberg; Edith Cowan University; Hollywood Private Hospital; Yale University School of Medicine; St. Vincent’s Health, University of Melbourne; National Ageing Research Institute, Parkville; CogState Ltd, Melbourne

  1. Faria, M. C., Gonçalves, G. S., Rocha, N. P., Moraes, E. N., Bicalho, M. A., Cintra, M. T. G., ... & Gomes, K. B. (2014). Increased plasma levels of BDNF and inflammatory markers in Alzheimer's disease. Journal of psychiatric research, 53, 166-172. https://www.ncbi.nlm.nih.gov/pubmed/24576746

  2. Forlenza, O. V., Diniz, B. S., Teixeira, A. L., Radanovic, M., Talib, L. L., Rocha, N. P., & Gattaz, W. F. (2015). Lower cerebrospinal fluid concentration of brain-derived neurotrophic factor predicts progression from mild cognitive impairment to Alzheimer’s disease. Neuromolecular medicine, 17(3), 326-332. https://www.ncbi.nlm.nih.gov/pubmed/26138246

  3. Pláteník, J., Fišar, Z., Buchal, R., Jirák, R., Kitzlerová, E., Zvěřová, M., & Raboch, J. (2014). GSK3β, CREB, and BDNF in peripheral blood of patients with Alzheimer's disease and depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 50, 83-93. https://www.ncbi.nlm.nih.gov/pubmed/24334212